Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma.
Paiva B, Pérez-Andrés M, Vídriales MB, Almeida J, de las Heras N, Mateos MV, López-Corral L, Gutiérrez NC, Blanco J, Oriol A, Hernández MT, de Arriba F, de Coca AG, Terol MJ, de la Rubia J, González Y, Martín A, Sureda A, Schmidt-Hieber M, Schmitz A, Johnsen HE, Lahuerta JJ, Bladé J, San-Miguel JF, Orfao A; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas); Myeloma Stem Cell Network (MSCNET). Paiva B, et al. Among authors: terol mj. Leukemia. 2011 Apr;25(4):697-706. doi: 10.1038/leu.2010.320. Epub 2011 Jan 21. Leukemia. 2011. PMID: 21252988
Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.
Paiva B, Gutiérrez NC, Chen X, Vídriales MB, Montalbán MÁ, Rosiñol L, Oriol A, Martínez-López J, Mateos MV, López-Corral L, Díaz-Rodríguez E, Pérez JJ, Fernández-Redondo E, de Arriba F, Palomera L, Bengoechea E, Terol MJ, de Paz R, Martin A, Hernández J, Orfao A, Lahuerta JJ, Bladé J, Pandiella A, Miguel JF; GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative. Paiva B, et al. Among authors: terol mj. Leukemia. 2012 Aug;26(8):1862-9. doi: 10.1038/leu.2012.42. Epub 2012 Feb 15. Leukemia. 2012. PMID: 22333880
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
Paiva B, Vídriales MB, Rosiñol L, Martínez-López J, Mateos MV, Ocio EM, Montalbán MÁ, Cordón L, Gutiérrez NC, Corchete L, Oriol A, Terol MJ, Echeveste MA, De Paz R, De Arriba F, Palomera L, de la Rubia J, Díaz-Mediavilla J, Granell M, Gorosquieta A, Alegre A, Orfao A, Lahuerta JJ, Bladé J, San Miguel JF; Grupo Español de MM/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group. Paiva B, et al. Among authors: terol mj. Leukemia. 2013 Oct;27(10):2056-61. doi: 10.1038/leu.2013.166. Epub 2013 Jun 7. Leukemia. 2013. PMID: 23743858
Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model.
Ferrer-Lores B, Ortiz-Algarra A, Picó-Peris A, Estepa-Fernández A, Bellvís-Bataller F, Weiss GJ, Fuster-Matanzo A, Fernández JP, Jimenez-Pastor A, Hernani R, Saus-Carreres A, Benzaquen A, Ventura L, Piñana JL, Teruel AB, Serrano-Alcalá A, Dosdá R, Sopena-Novales P, Balaguer-Rosello A, Guerreiro M, Sanz J, Martí-Bonmatí L, Terol MJ, Alberich-Bayarri Á. Ferrer-Lores B, et al. Among authors: terol mj. EJNMMI Res. 2024 Nov 20;14(1):113. doi: 10.1186/s13550-024-01172-9. EJNMMI Res. 2024. PMID: 39567446 Free PMC article.
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma.
Di Staso R, Casadei B, Locke FL, Jain M, Voorhees TJ, Kittai AS, Bastos-Oreiro M, Gutiérrez A, Martin Garcia-Sancho A, Terol MJ, Mead M, Maranzano MJ, Iacoboni G, Barba P, Kwon M, Bailen R, Reguera-Ortega JL, Mian A, Hill B, Bachy E, Morschhauser F, Houot R, Thieblemont C, Le Gouill S, Masetti R, Gori D, Broccoli A, Zinzani PL, Argnani L. Di Staso R, et al. Among authors: terol mj. Blood Cancer J. 2024 Nov 7;14(1):197. doi: 10.1038/s41408-024-01183-8. Blood Cancer J. 2024. PMID: 39511146 Free PMC article. No abstract available.
Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma.
Witzig T, Sokol L, Kim WS, de la Cruz Vicente F, Martín García-Sancho A, Advani R, Roncero Vidal JM, de Oña Navarrete R, Marín-Niebla A, Rodriguez Izquierdo A, Terol MJ, Domingo-Domenech E, Saunders A, Bendris N, Mackey J, Leoni M, Foss F. Witzig T, et al. Among authors: terol mj. Blood Adv. 2024 Sep 10;8(17):4581-4592. doi: 10.1182/bloodadvances.2024012806. Blood Adv. 2024. PMID: 38991123 Free PMC article. Clinical Trial.
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group.
Rey-Búa B, Grande C, Sánchez Blanco JJ, Abrisqueta P, Gutiérrez A, Ramírez Páyer Á, Giné E, Zeberio Etxetxipia I, Terol MJ, de la Cruz Vicente F, Andreu R, Ramirez MJ, de la Fuente A, Viguria MC, Peñarrubia MJ, Jiménez-Ubieto A, Montes-Moreno S, López-Guillermo A, Caballero MD, Martín García-Sancho A. Rey-Búa B, et al. Among authors: terol mj. Clin Cancer Res. 2024 Sep 3;30(17):3704-3714. doi: 10.1158/1078-0432.CCR-24-0183. Clin Cancer Res. 2024. PMID: 38900037 Clinical Trial.
Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).
Abrisqueta P, González-Barca E, Ferrà C, Ríos-Herranz E, Fernández de la Mata M, Delgado J, Andreu R, Hernández-Rivas JÁ, Terol MJ, Navarro A, Vidriales MB, Baltasar P, De la Serna J, Ramírez Á, Ballester C, Moreno C, García-Marco JA, Córdoba R, Yáñez L, Casado LF, González M, Bosch F. Abrisqueta P, et al. Among authors: terol mj. EClinicalMedicine. 2024 May 25;73:102642. doi: 10.1016/j.eclinm.2024.102642. eCollection 2024 Jul. EClinicalMedicine. 2024. PMID: 38841711 Free PMC article.
EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome.
Hernani R, Aiko M, Victorio R, Benzaquén A, Pérez A, Piñana JL, Hernández-Boluda JC, Amat P, Pastor-Galán I, Remigia MJ, Ferrer-Lores B, Micó M, Carbonell N, Ferreres J, Blasco-Cortés ML, Santonja JM, Dosdá R, Estellés R, Campos S, Martínez-Ciarpaglini C, Ferrández-Izquierdo A, Goterris R, Gómez M, Teruel A, Saus A, Ortiz A, Morello D, Martí E, Carretero C, Calabuig M, Tormo M, Terol MJ, Cases P, Solano C. Hernani R, et al. Among authors: terol mj. Clin Neurophysiol. 2024 Jul;163:132-142. doi: 10.1016/j.clinph.2024.04.014. Epub 2024 Apr 30. Clin Neurophysiol. 2024. PMID: 38733703 Free article.
127 results